The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)

The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)

Background Several studies have shown that combining immune checkpoint inhibitors (ICIs) with antiangiogenic tyrosine kinase inhibitors is effective for solid tumors, including esophageal squamous cell carcinoma (ESCC). However, most of these studies were focused on immunotherapy-naive patients. Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Xueru Zhu, Xiumei Ma, Hongxuan Li, Ming Zhang, Yan Cheng, Jianguo Wu, Wen Yu, Wen Feng, Lei Zhao, Zhigang Li, Xiaolong Fu, Jun Liu
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Annals of Medicine
Subjects:
Anlotinib
combination therapeutic regimen
esophageal squamous cell carcinoma
PD-1 inhibitor
progressed on prior ICI
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2024.2443811
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2024.2443811

Similar Items